{"id":1216,"date":"2024-07-31T10:04:18","date_gmt":"2024-07-31T02:04:18","guid":{"rendered":"https:\/\/flcube.com\/?p=1216"},"modified":"2024-10-14T22:15:15","modified_gmt":"2024-10-14T14:15:15","slug":"chinas-nmpa-approves-pilot-plan-to-streamline-clinical-trial-reviews-for-innovative-drugs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=1216","title":{"rendered":"China’s NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs"},"content":{"rendered":"\n

In a meeting chaired by Party Secretary and Director of the National Medical Products Administration (NMPA) Li Li on July 30, 2024, the “Pilot Work Plan for Optimizing Clinical Trial Review and Approval of Innovative Drugs” was given the green light. The initiative aims to enhance the quality and efficiency of drug clinical trials, with an ambitious target of reviewing and approving innovative drug clinical trial applications within 30 working days, thereby reducing the start-up time for such trials in the pilot regions.<\/p>\n\n\n\n

The pilot program will be implemented in areas that have demonstrated advanced clinical trial management and supportive policies, along with robust industrial capabilities in the clinical research and development of innovative drugs. The plan removes geographical restrictions for applicants seeking to participate in the pilot project, allowing for a more flexible and nationwide approach to clinical trial applications.<\/p>\n\n\n\n

The forthcoming “Pilot Work Plan for Optimizing Clinical Trial Review and Approval of Innovative Drugs” is set to be published shortly. The NMPA is committed to upholding principles of fairness, impartiality, and transparency in the review process, ensuring that all applications are rigorously assessed according to current technical standards. The administration has pledged to strengthen its collaboration with applicants, clinical trial institutions, and provincial drug regulatory authorities to facilitate the successful implementation of the pilot work.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

In a meeting chaired by Party Secretary and Director of the National Medical Products Administration…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[90,14],"class_list":["post-1216","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-clinical-trial-filings","tag-nmpa"],"yoast_head":"\nChina's NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"In a meeting chaired by Party Secretary and Director of the National Medical Products Administration (NMPA) Li Li on July 30, 2024, the "Pilot Work Plan for Optimizing Clinical Trial Review and Approval of Innovative Drugs" was given the green light. The initiative aims to enhance the quality and efficiency of drug clinical trials, with an ambitious target of reviewing and approving innovative drug clinical trial applications within 30 working days, thereby reducing the start-up time for such trials in the pilot regions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=1216\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China's NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=1216\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-31T02:04:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-14T14:15:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1216#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1216\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China’s NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs\",\"datePublished\":\"2024-07-31T02:04:18+00:00\",\"dateModified\":\"2024-10-14T14:15:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1216\"},\"wordCount\":231,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial filings\",\"NMPA\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1216#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1216\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=1216\",\"name\":\"China's NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-07-31T02:04:18+00:00\",\"dateModified\":\"2024-10-14T14:15:15+00:00\",\"description\":\"In a meeting chaired by Party Secretary and Director of the National Medical Products Administration (NMPA) Li Li on July 30, 2024, the \\\"Pilot Work Plan for Optimizing Clinical Trial Review and Approval of Innovative Drugs\\\" was given the green light. The initiative aims to enhance the quality and efficiency of drug clinical trials, with an ambitious target of reviewing and approving innovative drug clinical trial applications within 30 working days, thereby reducing the start-up time for such trials in the pilot regions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1216#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1216\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1216#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China’s NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs - Insight, China's Pharmaceutical Industry","description":"In a meeting chaired by Party Secretary and Director of the National Medical Products Administration (NMPA) Li Li on July 30, 2024, the \"Pilot Work Plan for Optimizing Clinical Trial Review and Approval of Innovative Drugs\" was given the green light. The initiative aims to enhance the quality and efficiency of drug clinical trials, with an ambitious target of reviewing and approving innovative drug clinical trial applications within 30 working days, thereby reducing the start-up time for such trials in the pilot regions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=1216","og_locale":"en_US","og_type":"article","og_title":"China's NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=1216","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-07-31T02:04:18+00:00","article_modified_time":"2024-10-14T14:15:15+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=1216#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=1216"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China’s NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs","datePublished":"2024-07-31T02:04:18+00:00","dateModified":"2024-10-14T14:15:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=1216"},"wordCount":231,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial filings","NMPA"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=1216#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=1216","url":"https:\/\/flcube.com\/?p=1216","name":"China's NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-07-31T02:04:18+00:00","dateModified":"2024-10-14T14:15:15+00:00","description":"In a meeting chaired by Party Secretary and Director of the National Medical Products Administration (NMPA) Li Li on July 30, 2024, the \"Pilot Work Plan for Optimizing Clinical Trial Review and Approval of Innovative Drugs\" was given the green light. The initiative aims to enhance the quality and efficiency of drug clinical trials, with an ambitious target of reviewing and approving innovative drug clinical trial applications within 30 working days, thereby reducing the start-up time for such trials in the pilot regions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=1216#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=1216"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=1216#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China’s NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1216"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1216\/revisions"}],"predecessor-version":[{"id":6494,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1216\/revisions\/6494"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}